


Trimetrexate

Chemical Properties

CAS No.:	52128-35-5
Formula:	C ₁₉ H ₂₃ N ₅ O ₃
Molecular Weight:	369.42
Appearance:	N/A
Storage:	0-4°C for short term (days to weeks), or -20°C for long term (months).



Biological Description

Description	Trimetrexate is an effective competitive inhibitor of bacterial, protozoan, and mammalian dihydrofolate reductase.
Targets(IC ₅₀)	Others: None
In vitro	Trimetrexate and leucovorin are safe and effective for the initial treatment of pneumocystis pneumonia in patients with AIDS and for the treatment of patients with intolerance or lack of response to standard therapies. In noncomparative trials, trimetrexate was effective in the treatment of P. carinii pneumonia (PCP) in patients with AIDS who were intolerant of or refractory to cotrimoxazole (trimethoprim/sulfamethoxazole) and pentamidine treatment. In these patients, 2- to 4-week survival rates of 48 to 69% were reported. Trimetrexate plus leucovorin was effective, albeit inferior to TMP-SMZ, for moderately severe P. carinii pneumonia but was better tolerated than TMP-SMZ [1][2][3].

Solubility Information

Solubility	DMSO: 61.5 mg/mL (166.48 mM) (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	-------------------------------------------------------------------------------------------------

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.707 mL	13.535 mL	27.069 mL
5 mM	0.541 mL	2.707 mL	5.414 mL
10 mM	0.271 mL	1.353 mL	2.707 mL
50 mM	0.054 mL	0.271 mL	0.541 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

Reference

1. Allegra CJ, et al. Trimetrexate for the treatment of *Pneumocystis carinii* pneumonia in patients with the acquired immunodeficiency syndrome. *N Engl J Med*. 1987 Oct 15;317(16):978-85.
2. Fulton B, et al. Trimetrexate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of *Pneumocystis carinii* pneumonia. *Drugs*. 1995 Apr;49(4):563-76.
3. Sattler FR, et al. Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of *Pneumocystis carinii* pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group Protocol 029/031. *J Infect Dis*. 1994 Jul;170(1):165-72.

[Inhibitors](#) · [Natural Compounds](#) · [Compound Libraries](#)

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use.

Tel:781-999-4286

E-mail:info@targetmol.com

Address:36 Washington Street,Wellesley Hills,MA 02481